Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol

Peter-Paul Willemse

doi:10.1136/bmjopen-2020-040531

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol

Research output: Contribution to journal › Review article › peer-review

Abstract

INTRODUCTION: As part of the PIONEER (Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe) Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).

METHODS AND ANALYSIS: This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) risk of bias assessment and applicability with Prediction model Risk Of Bias Assessment Tool criteria, Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and the Quality In Prognosis Studies tool (QUIPS) and (4) additional quantitative assessments if required.

ETHICS AND DISSEMINATION: We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.

Original language	English
Article number	e040531
Journal	BMJ Open
Volume	11
Issue number	2
DOIs	https://doi.org/10.1136/bmjopen-2020-040531
Publication status	Published - 11 Feb 2021

Keywords

Bias
Europe
Humans
Male
Prognosis
Prostatic Neoplasms/diagnosis
Systematic Reviews as Topic
Urological tumours
Prostate disease
Oncology

Access to Document

10.1136/bmjopen-2020-040531

Cite this

@article{c35d0dd74a734a0e9944d45998d7dd20,

title = "Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol",

abstract = "INTRODUCTION: As part of the PIONEER (Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe) Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).METHODS AND ANALYSIS: This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) risk of bias assessment and applicability with Prediction model Risk Of Bias Assessment Tool criteria, Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and the Quality In Prognosis Studies tool (QUIPS) and (4) additional quantitative assessments if required.ETHICS AND DISSEMINATION: We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.",

keywords = "Bias, Europe, Humans, Male, Prognosis, Prostatic Neoplasms/diagnosis, Systematic Reviews as Topic, Urological tumours, Prostate disease, Oncology",

author = "Katharina Beyer and Lisa Moris and Michael Lardas and Anna Haire and Francesco Barletta and Simone Scuderi and Eleni Vradi and Giorgio Gandaglia and Omar, {Muhammad Imran} and Steven MacLennan and Jihong Zong and Bahman Farahmand and Maclennan, {Sara J} and Zsuzsanna Devecseri and Alex Asiimwe and Laurence Collette and Anders Bjartell and James Ndow and Alberto Briganti and {Van Hemelrijck}, Mieke and Peter-Paul Willemse",

note = "Funding Information: grant agreement No. 777492. IMI2 receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Funding Information: Funding PIONEER is funded through the IMI2 Joint Undertaking and is listed under Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.",

year = "2021",

month = feb,

day = "11",

doi = "10.1136/bmjopen-2020-040531",

language = "English",

volume = "11",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group",

number = "2",

}

TY - JOUR

T1 - Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol

AU - Beyer, Katharina

AU - Moris, Lisa

AU - Lardas, Michael

AU - Haire, Anna

AU - Barletta, Francesco

AU - Scuderi, Simone

AU - Vradi, Eleni

AU - Gandaglia, Giorgio

AU - Omar, Muhammad Imran

AU - MacLennan, Steven

AU - Zong, Jihong

AU - Farahmand, Bahman

AU - Maclennan, Sara J

AU - Devecseri, Zsuzsanna

AU - Asiimwe, Alex

AU - Collette, Laurence

AU - Bjartell, Anders

AU - Ndow, James

AU - Briganti, Alberto

AU - Van Hemelrijck, Mieke

AU - Willemse, Peter-Paul

N1 - Funding Information: grant agreement No. 777492. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Funding Information: Funding PIONEER is funded through the IMI2 Joint Undertaking and is listed under Publisher Copyright: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

PY - 2021/2/11

Y1 - 2021/2/11

N2 - INTRODUCTION: As part of the PIONEER (Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe) Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).METHODS AND ANALYSIS: This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) risk of bias assessment and applicability with Prediction model Risk Of Bias Assessment Tool criteria, Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and the Quality In Prognosis Studies tool (QUIPS) and (4) additional quantitative assessments if required.ETHICS AND DISSEMINATION: We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.

AB - INTRODUCTION: As part of the PIONEER (Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe) Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).METHODS AND ANALYSIS: This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) risk of bias assessment and applicability with Prediction model Risk Of Bias Assessment Tool criteria, Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and the Quality In Prognosis Studies tool (QUIPS) and (4) additional quantitative assessments if required.ETHICS AND DISSEMINATION: We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.

KW - Bias

KW - Europe

KW - Humans

KW - Male

KW - Prognosis

KW - Prostatic Neoplasms/diagnosis

KW - Systematic Reviews as Topic

KW - Urological tumours

KW - Prostate disease

KW - Oncology

UR - http://www.scopus.com/inward/record.url?scp=85100831811&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2020-040531

DO - 10.1136/bmjopen-2020-040531

M3 - Review article

C2 - 33574142

SN - 2044-6055

VL - 11

JO - BMJ Open

JF - BMJ Open

IS - 2

M1 - e040531

ER -

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this